WHO Informal Consultation on standardization and evaluation of BCG vaccines Geneva, Switzerland 22-23 September 2009.
The current World Health Organization Requirements for BCG vaccine are in need of revision to address the diversity of sub-strains used for production, potential improvements of quality control assays for lot release, and the establishment of sub-strain specific Reference Reagents. A consultation meeting was organized to discuss issues regarding the standardization and evaluation of BCG vaccines in the forum of regulators, BCG vaccine manufacturers, developers of selected new live tuberculosis (TB) vaccines and researchers. The development of new recombinant BCG and live attenuated TB vaccines and the characterisation of different BCG sub-strains using state-of-the-art technologies were also reviewed. The objective of the meeting was to revise and update the current recommendations focused on the scope, terminology, manufacturing issues, and the incorporation of new reference reagents and new quality control tests.
Ho
Mei M
MM
Bacteriology Division, NIBSC-HPA, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK. mei.ho@nibsc.hpa.org.uk
Southern
James
J
Kang
Hye-Na
HN
Knezevic
Ivana
I
D001500:BCG Vaccine / Q000592:standards*; D002986:Clinical Trials as Topic; D009163:Mycobacterium bovis / Q000145:classification / Q000235:genetics; D011786:Quality Control; D012015:Reference Standards; D014613:Vaccines, Attenuated / Q000592:standards; D014944:World Health Organization
D001500:BCG Vaccine; D014613:Vaccines, Attenuated